CRISPR-Cas systems are bacterial adaptive immune pathways that have revolutionized biotechnology 24 and biomedical applications. Despite the potential for human therapeutic development, there are many 25 hurdles that must be overcome before its use in clinical settings. Some clinical safety concerns arise from 26
dCas9-based imaging, epigenetic modification, and genetic circuits (Pawluk et 
Validation of microRNA-repressible anti-CRISPR expression vectors 151
We used a human hepatocellular carcinoma cell line (Huh-7) that abundantly expresses miR-122, in 152 contrast to non-hepatic cell lines such as human embryonic kidney (HEK293T) cells (Fukuhara et al. 153 2012) . As an initial test of miR-122 repression of Acr expression, we transfected cells with plasmids 154 expressing AcrIIC3-FLAG-mCherry-3xmiR122BS, AcrIIA4-FLAG-mCherry-3xmiR122BS, or their 155 respective control vectors lacking the miR-122 binding sites (Fig. 1B) . A separate GFP expression plasmid 156 was also included to indicate transfection efficiencies in each cell line. When these vectors were transiently 157 transfected, the expression of mCherry-fused Acr with miR-122 MREs was dramatically suppressed in 158
Huh7 cells whereas Acr-mCherry lacking 3xmiR122BS was still well expressed ( Fig. 2A) . In HEK293T 159 cells, there was no discernible difference in mCherry signal from the Acr and Acr-3xmiR122BS constructs 160 based on both fluorescence microscopy and flow cytometry (Fig. 2B) . Acr expression was also confirmed 161 by anti-FLAG western blot analysis (Fig. 2) . Compared to HEK293T cells, transfection efficiency was 162 lower in Huh-7 cells as indicated by a decrease in overall GFP and mCherry signals ( Fig. 2A) . 163
Nevertheless, fluorescence microscopy, flow cytometry, and Western blot analysis consistently revealed 164 effective reductions of both AcrIIC3-3xmiR122BS and AcrIIA4-3xmiR122BS expression in Huh-7, but 165 not in HEK293T cells. Expression of Acrs lacking miR-122 MREs was unaffected in both cell lines, 166 consistent with effective regulation of Acr by miR-122 only in hepatic cells. 167
168

MicroRNA repression enables escape from anti-CRISPR inhibition during genome editing 169 in hepatocytes 170
Having demonstrated that anti-CRISPR repression in hepatocyte-derived cells can be conferred by miR-171
122 MREs, we then tested whether this repression is sufficient to allow genome editing by Cas9 orthologs 172 (SpyCas9, Nme1Cas9 and Nme2Cas9). We transiently transfected separate expression plasmids for Cas9,Nme1Cas9 target site NTS33 in the VEGFA gene (Fig. 3A) , the Nme2Cas9 target site TS6 in the 176 LINC01588 gene (Fig. 3B) , and the SpyCas9 target site 1617 in the BCL11A enhancer (Fig. 3C) (Fig. 3) . The presence or absence of miR-122 MREs had no significant effect on 180 editing inhibition in this non-miR-122-expressing cell type. Although the editing efficiency was variable 181 among Cas9 orthologs at these target sites, and although transfection efficiencies were reduced in Huh-7 182 cells, AcrIIC3Nme and AcrIIA4Lmo also prevented editing in this cell type when expressed from constructs 183 that lack miR-122 MREs. By contrast, Acrs plasmids that incorporated miR-122 MREs in the 3'UTRs 184 failed to inhibit Cas9 editing in Huh-7 cells, as indicated by editing efficiencies that were similar to the no-185
Acr control (Fig. 3 ). This trend was true for all three Cas9 orthologs tested. 186 187
MiR-122-dependent in vivo genome editing conferred by an anti-CRISPR protein 188
For our in vivo tests we focused on Nme2Cas9, due to its compact size, high target site density, and relative 189 lack of off-target editing, all of which are advantageous for therapeutic development. We used a 190 previously validated all-in-one AAV vector that expresses Nme2Cas9 from the minimal U1a promoter, as 191 well as a U6 promoter-driven sgRNA targeting Rosa26 (Ibraheim et al. 2018; Edraki et al. 2018) (Fig. 4A) . 192
We also generated AcrIIC3Nme expression plasmids driven by the strong CB-PI promoter and associated 193 expression elements; in addition, these AcrIIC3Nme constructs either included or omitted the three tandem 194 miR-122 MREs in the 3' UTR (Fig. 4A) . For in vivo delivery we used hydrodynamic injection, which is a 195 non-viral method of transient hepatocyte transfection that allows expression from naked DNA plasmids 196 (Zhang et al. 1999 ). This injection method delivers DNA to ~20% of hepatocytes for transient expression 197
and has minimal transgene expression in organs other than the liver. Since miR-122 is abundant in the 198 liver, and because Cas9 delivered to the liver by hydrodynamic injection can induce editing (Xue et al. 199
vein and liver tissues were collected at 7 days post-injection (Fig. 4B) . To determine the effective dose of 202 Acr plasmid needed to inhibit Nme2Cas9 editing in vivo, we co-injected varying Cas9:Acr plasmid ratios 203
(1:1, 1:1.5, and 1:2). AcrIIC3Nme efficiently inhibited Nme2Cas9 editing at all ratios tested (Fig. 4C) . No 204 apparent liver damage was detected in the liver tissues following staining with haemotoxylin and eosin 205 (H&E) (Supplemental Fig. 2 ). Once we defined the necessary plasmid dose, we subjected three groups of 206 mice to hydrodynamic injection with plasmid combinations that included Nme2Cas9 with (i) no Acr, (ii) 207
AcrIIC3Nme, and (iii) AcrIIC3Nme-3xmiR122BS ( that opportunities for implementing this strategy will continue to increase. We also note that expression 248 profiles of many miRNAs are well-defined for many tissues at many developmental stages and in 249 numerous disease states (Alvarez-Garcia and Miska 2005). For example, miR-1 is highly and specifically 250 expressed in cardiac and skeletal muscle tissues (Horak et al. 2016). The miRNA-repressible Acr system 251 affords great flexibility in changing editing tissue specificity, given the ease with which the MREs can beswapped in the 3'UTR of the Acr transcript. Furthermore, because MREs are so small, this approach is 253 well suited for viral modes of delivery (given the genome capacity constraints of viral vectors), and could 254 confer specificity for some tissues that lack vector-compatible, tissue-specific promoters. 255
256
We extend this strategy to animal studies that document anti-CRISPR efficacy during Cas9-mediated 257 editing in vivo. To our knowledge, this is the first demonstration of in vivo expression of Acr proteins in 258 vertebrate models to inhibit Cas9 editing activity. From this study, we did not observe overt toxicity in the 259 transfected liver tissues, although the safety and immunity profiles of delivered Acr proteins will need to 260 be examined over longer periods of time and in additional biological contexts. 
Materials and Methods 277 278
Vector construction 279
Codon-optimized AcrIIC3Nme and AcrIIA4Lmo sequences were ordered as gBlocks (IDT) and amplified 280 using the primers with overhangs to the pCSDest vector by NEBuilder® HiFi DNA Assembly (NEB). 281
Similarly, an mCherry ORF was fused to the C-terminus of each Acr by HiFi DNA assembly (NEB). To 282 Western blot analysis, 500 ng of each Acr vector and GFP plasmid used as a transfection control were 297 transfected in a 6-well format using Lipofectamine 2000 (Invitrogen). The total DNA amount was kept 298 constant by adding a stuffer plasmid in all cases. 299
Flow cytometry 301
Transfected cells were trypsinized, washed in PBS, and resuspended in PBS for analysis on a 302
MACSQuant® VYB from Miltenyi Biotec. A yellow laser (561 nm) with a 615/20 nm filter and a blue 303 laser (488 nm) with a 525/50 nm filter were used for mCherry and GFP detection, respectively. of Massachusetts Medical School. Plasmids for hydrodynamic tail-vein injection were prepared using the 320 EndoFreeMaxi kit (Qiagen). For hydrodynamic liver injection, a total of 90 ug of endotoxin-free plasmids 321 was suspended in 2 ml of injection-grade saline and injected via the tail vein into 8-to 10-week-old 322 C57BL/6 mice. Mice were euthanized 7 days post-injection and liver tissues were collected and stored at 323 -80°C for analyses. 324
Indel analysis 326
Genomic DNA from cells or liver tissues were collected using DNeasy Blood & Tissue Kit (Qiagen). 327
Target sites were amplified using High Fidelity 2X PCR Master Mix (NEB). Primers used for PCR are 328 listed in Supplementary Materials. PCR products were purified using DNA Clean & Concentrator Kit 329 (Zymo) and sent for Sanger sequencing to obtain trace files (Genewiz). Indel values were estimated using 330 the TIDE web tool (https://tide-calculator.nki.nl/). 331 332
Statistical analysis 333
Standard deviations are derived from each group that has a minimum of three independent replicates 334 unless otherwise noted. Unpaired, two-tailed t-test was used to determine the statistical significance 335 between each group. Resulting P-values < 0.05, 0.01 and 0.001 are indicated by one, two, or three 336 asterisks, respectively. 337
338
Imunohistochemistry 339
Liver tissues were fixed in 4% formalin overnight, paraffin-embedded, and sectioned at the UMass
Supplemental Materials 352
Supplemental materials are available for this article. 353
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